Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P39905
UPID:
GDNF_HUMAN
Alternative names:
Astrocyte-derived trophic factor
Alternative UPACC:
P39905; B7WPK7; O95448; O95449; O95986; Q6FH33; Q96L44; Q9UD32; Q9UD33; Q9UMV2; Q9UP67; Q9UP97
Background:
Glial cell line-derived neurotrophic factor (GDNF), also known as Astrocyte-derived trophic factor, plays a pivotal role in the survival, development, and function of dopaminergic neurons. Its ability to enhance high-affinity dopamine uptake highlights its significance in neural function.
Therapeutic significance:
GDNF's involvement in Hirschsprung disease 3 and Pheochromocytoma underscores its potential in therapeutic strategies targeting neural crest development disorders and catecholamine-producing tumors. Understanding GDNF's role could revolutionize treatments for these conditions.